Posted by Michael Wonder on 04 May 2020
NDA filing for potential new ADHD treatment, KP415, accepted by FDA
4 May 2020 - Corium, GPC’s portfolio company, to lead all commercialisation activities for KP415.
KemPharm today confirmed that the U.S. FDA has accepted the new drug application for its investigational product candidate, KP415.
KP415 is KemPharm’s product candidate for the treatment of attention deficit hyperactivity disorder, which contains serdexmethylphenidate, KemPharm’s prodrug of d-methylphenidate.
